Spyryx Biosciences

November 4, 2016November 4, 2016

Preclinical Studies Show Promise for Cystic Fibrosis Therapy in Early Clinical Testing

Cystic Fibrosis, News

SPX-101, an investigational drug for the treatment of cystic fibrosis (CF) being developed by Spyryx Biosciences, has shown to be a safe, stable, and efficient therapy in animal models of the ... Read more

June 29, 2015November 5, 2015

CFFT Awards Spyryx Biosciences to Advance Novel CF Therapy

Cystic Fibrosis, News

Spyryx Biosciences, Inc. has been granted an award from Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation (CFF). The funding will be invested ... Read more

May 11, 2015November 9, 2015

Cystic Fibrosis And COPD Specialist Firm Spyryx Biosciences Announces $18 Million Series A Funding

COPD, Cystic Fibrosis, News

Spyryx Biosciences Inc., a privately-held biopharmaceutical company specializing in development of novel therapeutics for respiratory diseases, including cystic fibrosis (CF) and chronic obstructive pulmonary disorder (COPD), announced Thursday that it ... Read more